Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.
Basata raises $21m as investors target the hidden cost of healthcare administration
Healthcare AI is moving from diagnosis to operations. Basata’s $21M raise tests whether referrals and scheduling can finally escape fax-era friction.